Senior Partners

Ajinomoto BioPharma Services logo

Ajinomoto BioPharma Services

Senior Partner

Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and biologics production, from process development and cGMP manufacturing to aseptic fill finish, including cytotoxics. As a global CDMO, we provide the adaptive solutions, responsive service, trusted partnership and peace of mind you’ve come to rely on.  Ajinomoto Bio-Pharma Services is establishing itself as a premier, US-based provider for high-containment bioconjugate manufacturing, as well as fill and finish services for both Highly Potent Active Pharmaceutical Intermediates (HPAPI) and Antibody Drug Conjugates (ADC).



Senior Partner

Merck is the leading Life Science company, providing solutions as a strategic partner to help advance the promise of life-saving therapies. We have the largest offering of products for formulations, actives, and biotechnology processes. Our joint ADC offering includes a full range of integrated contract manufacturing services for drug development and manufacturing that spans conjugation, mAbs, linkers, and payloads. To fit your ADC manufacturing needs, we offer a comprehensive processing portfolio from cell culture media to buffers, salts, and stabilizers and from chromatography to TFF equipment, including single-use templates.

Antibody-Drug Conjugate (ADC) Manufacturing (

NJ Bio

NJ Bio

Senior Partner

NJ Bio is a US-based CRO that provides high-quality integrated chemistry and biology services for bioconjugations and ADCs to biotech and pharmaceutical companies – from start-up to big pharma. Main service areas include linker-payload synthesis for ADCs, bioconjugations and antibody-drug conjugates as well as bioassay and bioanalytical services. With our expertise and experience in the ADC field, we strive to create value for our clients by advancing their programs. Please contact or visit our website.

Sotio_lg (002)


Senior Partner

SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. The robust SOTIO clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, SOT101, currently being tested in phase II clinical trials. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, and IL-15-based immunocytokine, BOXR1030, a GPC3-targeted CAR-T and SOT102, a next generation Claudin18.2-targeted antibody-drug conjugate. SOTIO is a member of the PPF Group.



Senior Partner

Synaffix is a biotech company with a proprietary, clinical-stage ADC platform technology enabling ADCs with improved therapeutic index compared to all 3 major clinical-stage ADC technologies. 

Our consolidated technology platform includes GlycoConnect™ antibody conjugation, HydraSpace™ polar spacer and toxSYN™ linker-payload technologies, which can be accessed together by any company with an antibody, to develop their own proprietary, best-in-class ADC.

Our technology out-licensing business has already translated into 3 clinical-stage ADCs, at least 15 distinct ADC programs being developed across our 9 partners and well over $3Bn in total potential value from our out-licensing deals.





AbTis is the bio-technology company which specializes in antibody-drug Conjugation technology and Solubilization of drugs through Micelle format with its own proprietary patents.

Our pipelines are designed to enhance the safety and efficacy of the current antibody drug conjugates by applying AbTis linker to the mAbs.Our technology is applicable to the native antibodies, commercial antibodies or novel antibodies under development as it requires no mutation or engineering to antibody itself.

AbTis is one of the leading bio-conjugation companies. We seek to create positive economic impact and long-term value, improved quality of life for the patients worldwide. AbTis was founded in 2016 by Professor Sang Jeon Chung, our Chairman and Chief Executive Officer, in 2017 it was seed funded $ 0.5 million and 2018 June, we secured $ 4.5 million private placement from 3 venture capital firms which are Stonebridge capital partners, K2 Investment and JX partners.





We are Abzena – Built to deliver. Created to care.

Abzena is a global development and manufacturing partner that provides integrated discovery, development and manufacturing services for biologics and bioconjugates to the biopharmaceutical industry. We help our partners to take their innovative discoveries from early-phase development through to commercial manufacture by tailoring our approach from concept to clinic. Our vision is to accelerate the development of biologic treatments and bioconjugates so that suffering of patients is prevented, and lifespan improved.


4971_Beacon-ADC_2021 (002)



We are a competitive and research intelligence database solution designed in partnership with pharmaceutical professionals across the world. We work in targeted therapies such as targeted protein degradation to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.  

Find out more on how we can help you by visiting our website:


BSP 2 (002)

BSP Pharmaceuticals


BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic  drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. BSP Pharmaceuticals is focused on innovative therapies such as Proteosome Inhibitors, Antibody Drug Conjugates (ADCs) , Liposomal formulations, handling the major platforms of ADC compounds currently in clinical and commercial phase.




CARBOGEN AMCIS combines world-class chemistry skills to provide seamless drug development and commercialization services for pharmaceutical and biotechnology companies. Through our customized offering we provide an array of integrated process research and manufacturing services to support the fast supply of complex Antibody Drug Conjugates (ADCs). Our infrastructure is fully cGMP compliant and includes a clean room dedicated to ADCs in Switzerland and a formulation site with lyophilization capabilities in France.

Catalent Biologics logo

Catalent Biologics


Catalent Biologics provides advanced technologies and solutions for protein and gene therapy development, manufacturing and clinical supply. With technology platforms including GPEx® cell line engineering, SMARTag® bioconjugation and AAV viral vector expression combined with comprehensive analytical services and fill/finish supply, Catalent Biologics is your premier partner for clinical and commercial success.




We are a reliable supplier of HPAPIs for the pharmaceutical industry specialized in fighting cancer.

Besides our platinum-based and organic HPAPIs, we have an extensive knowledge in manufacturing and purification of different payload and linker classes in the ADC field.

As CDMO we support our customers in the exclusive synthesis of cytotoxic compounds from research stage to registration and market launch.

Heraeus, headquartered in Hanau, Germany, is a leading international family-owned company formed in 1851.


ILC Dover


ILC Dover is a world-leader in the innovative design and production of engineered flexible protective solutions. Based in Frederica, Delaware, we serve the pharmaceutical industry with single-use flexible powder solutions that facilitate safe and reliable performance and productivity in the lab. CMOs and CDMOs choose our solutions for powder transfers and containment over rigid stainless-steel systems, for the significant advantages they bring to chemical synthesis of HPAPI and OSD processing for final drug products.




Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We perform ADC sample preparation, small scale development services, customized facility design, and superior scale up of early stage processes for late stage and commercial supply. Backed by a strong reputation for industry leading analytical capabilities and quality control, Lonza can also aide in driving quick development and improving marketability of the industry’s high potential future therapies Contact or visit


NJ Bio


NJ Bio is a US-based CRO that provides high-quality integrated chemistry and biology services for bioconjugations and ADCs to biotech and pharmaceutical companies – from start-up to big pharma. Main service areas include linker-payload synthesis for ADCs, bioconjugations and antibody-drug conjugates as well as bioassay and bioanalytical services. With our expertise and experience in the ADC field, we strive to create value for our clients by advancing their programs. Please contact or visit our website.




Novasep has been a leading contract service provider in the ADC arena for more than 10 years and provides unique services for the development, clinical supply and commercial manufacture of antibody-drug conjugates including the payload, the linker and the monoclonal antibody.

Our commitment to ADCs is underlined by the recent €11M investment in a stand-alone bioconjugation unit at our Le Mans site in France. The site has more than 30 years of experience in synthesis & purification of cytotoxics using industrial chromatography.


Piramal Pharma Solutions Logo (PRNewsfoto/Piramal Pharma Solutions)



Piramal Pharma Solutions is a contract development and manufacturing organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our clients through a globally integrated network of facilities in North America, Europe and Asia. This enables us to offer a comprehensive range of services including Drug Discovery Solutions, Process & Pharmaceutical Development services, Clinical Trial Supplies, Commercial supply of APIs and Finished dosage forms. We also offer specialized services like development and manufacture of Highly Potent APIs and Antibody Drug Conjugation. Our capability as an integrated service provider & experience with various technologies enables us to serve Innovator and Generic companies worldwide.






Formed in 2015, PROVEO is now a Division of Cerbios- Pharma SA focused on complete supply chain solution for Antibody Drug Conjugates (ADCs).
Thanks to the partnership with AGC Biologics and Oncotec, PROVEO offer best-in-class solutions for the integrated development and cGMP manufacturing of recombinant proteins (incl mAbs), cytotoxic drug-linker payload, conjugation, aseptic fill and lyophilization. Strengths of the three PROVEO partners secure a seamless and low risk ADC supply chain for clinical and commercial projects.




The Sartorius Group is a leading international partner of the biopharmaceutical industry and the research sector. We are helping biotech scientists and engineers across the entire globe to develop and manufacture medications from the first idea to production. So more people will have access to better medicine.


Savid Therapeutics


Savid Therapeutics, Inc. is a preclinical stage cancer therapeutic company with a novel and proprietary antibody mimetic drug conjugate (AMDC) platform that harnesses unparalleled binding strength and flexibility of avidin-biotin chemistry to deliver multiple therapeutic payloads to multiple cancer cell targets. As an enabling technology for cancer therapeutics, diagnostic, and imaging, the Cupid-Psyche platform insures a tight and specific linkage between tumor specific antigen targets and therapeutic payloads delivering the most effective therapies to only the targeted tissues.




VERAXA combines game-changing technologies of next generation ADC technology and microfluidic mAb screening. VERAXA is a technology-based biotech company based in Heidelberg, which provides a superior ADC platform technology by combining genetic code expansion and bioorthogonal click chemistry, allowing for conjugation at any position with the highest reproducibility. VERAXA offers versatile partnering options for superior ADC candidates with optimal properties, through selectable position and highly efficient, hydrophilic, and stable conjugation, to de-risk clinical development paths.

WuXi Biologics

WuXi Biologics


Exhibition Partners


A&G Pharmaceutical

Exhibition Partner


Aptamer Group IDs

Aptamer Group

Exhibition Partner

Aptamer Group is the developer of custom affinity tools for the life science industry through its proprietary Optimer® platform.

Optimer binders are nucleic acid-based affinity ligands that can be used as an antibody alternative to offer novel solutions and improvements to current processes across the therapeutic, diagnostic, bioprocessing and research sectors. The Optimer platform consists of three parallel processes optimized for target type to enable scientists with the best affinity ligand for small molecules, proteins or cell targets.

Offering rapid development in just weeks, full platform compatibility and tuneable binding kinetics to ensure desired end-use performance, Optimer binders are enabling new insights and new molecules to progress life science for better healthcare for all.


euroAPI_Logo_Signat_RVB (002)


Exhibition Partner

Euroapi is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a world leader in active pharmaceutical ingredients with some 200 products in our portfolio, offering a large span of technologies, while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO).

Taking action for health by enabling access to essential therapies inspires our 3,350 people every day. With strong research and development capabilities and six manufacturing sites all located in Europe, Euroapi ensures API manufacturing of the highest quality to supply customers in more than 80 countries.


GTP Bioways

Exhibition Partner

TP Bioways is an expert CDMO offering end-to-end services for the manufacturing of antibody conjugates. Thanks to our strategic partnership with Fareva, we have the facilities and expertise to handle the manufacturing of the mAb, the conjugation process and the aseptic fill and finish. With our customised approach and expert-level knowledge, we are perfectly set up to take your drug development all the way to clinic. Over nearly a decade, our team has successfully managed ADCs projects based on various conjugation technologies for clinical trials, up to phase II.



Exhibition Partner

Intertek Pharmaceutical Services – Bringing Quality and Safety to Life.

With nearly three decades of experience in large molecule bioanalysis and characterization, our experts have considerable knowledge of the evolving regulatory framework across various regions and the scientific background of this product class. By bringing quality and safety to life, our scientists work with clients globally, helping them meet all regulatory expectations and specifications for successful drug substance and drug product release. For ADCs, we provide expertise in GLP/GMP laboratory testing, bioanalysis, characterization, purity and impurity profile, stability testing and comparability, and more – all delivered consistently with precision, pace, and passion, allowing you to power ahead safely.



Exhibition Partner



Exhibition Partner



Exhibition Partner

Minakem is a technology driven outsourcing partner dedicated to developing and manufacturing fine chemicals, advanced intermediates, APIs and HPAPIs including ADC toxins. A dedicated site having more than 40 years’ experience in high potent compounds, with state-of-the-art containment systems and capability to handle broad range of chemistry from grams to kilos scale, including preparative-HPLC, makes Minakem a partner of choice in HPAPI and ADC toxins development and supply across the full product life cycle.

olon png


Exhibition Partner

Olon is an Italian company world leader in the Active Pharmaceutical Ingredients (APIs) production, using synthetic and biological processes for Generic market as well as in Contract Development and Manufacturing (CDMO).

With a 2020’s Turnover of 530 Mio$, OLON supplies 34 Chemical Intermediates and more than 295 APIs for the Generic market.

Thanks to all the 2.300 employees, and to highly qualified R&D team – more than 200 people – OLON can offer complete integrated packages and services to support the full development of APIs based on strong knowledge in both Chemical and Biological process, all of them under a full cGMP and regulatory coverage. Headquartered in Italy, the Group has 11 manufacturing facilities globally.


Quality Assistance

Exhibition Partner



Sterling Full Colour Logo


Exhibition Partner

Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO), with 50 years’ experience in small molecule API development and manufacturing services. In December 2020 Sterling made a significant investment in ADC Bio, a UK based biotechnology company specialising in antibody drug conjugates and bioconjugation, and is working towards completing a full acquisition by the end of Q1 2021. Together, as Sterling Pharma Solution, the teams will develop an integrated service offering for existing and potential customers, which combines ADC Bio’s expertise with Sterling’s high potency small molecule expertise.

gore_logo_color_positive_rgb (002)

WL Gore

Exhibition Partner

Gore PharmBIO is committed to providing leading edge Pharmaceutical companies innovative, pure and secure drug processing, packaging, and delivery options through revolutionary materials science and uniquely applied engineering. Working together with our customers, we help create peace of mind and improve the lives of patients every day.